Brief: Roche Says FDA Accepts Roche NDA For Fenebrutinib Under Priority Review
30/09/2026 06:04
BRIEF-Roche Says FDA Accepts Roche NDA For Fenebrutinib Under Priority Review Sept 30 (Reuters) - ROCHE HOLDING AG ROPC.S:
ROCHE’S FENEBRUTINIB IS THE FIRST BTK INHIBITOR TO RECEIVE U.S. FDA FILING ACCEPTANCE IN BOTH RELAPSING AND PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
FDA ACCEPTS ROCHE NDA FOR FENEBRUTINIB UNDER PRIORITY REVIEW
FENEBRUTINIB REDUCED RELAPSES BY 51% AND 58% VERSUS TERIFLUNOMIDE IN PHASE III RMS TRIALS
FENEBRUTINIB SLOWED DISABILITY PROGRESSION IN PHASE III PPMS TRIAL VERSUS OCREVUS
Source text: ID:nGNE3s24HB
Further company coverage: ROPC.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 587785269;))
Recent news on Roche Holding AG
See all newsNovartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
Brief: Roche Says Sefaxersen Achieved Statistically Significant 43.1% Reduction In Proteinuria In Interim Phase III Data
Brief: Zymeworks Signs Exclusive Global Licensing Deal With Roche For Cancer Drug ZW209
Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal
DB ups Roche to 'buy' on positive oncology survey